Which medications should be initiated for a patient with newly diagnosed heart failure?

Initial Medication Therapy for New-Onset Heart Failure

For newly diagnosed heart failure with reduced ejection fraction (HFrEF), you should initiate quadruple therapy consisting of: (1) an ACE inhibitor or ARNI, (2) a beta-blocker, (3) a mineralocorticoid receptor antagonist (MRA), and (4) an SGLT2 inhibitor—all started simultaneously at low doses and uptitrated to target doses as tolerated. 1, 2

Core Foundation: The Four Pillars

The modern approach to HFrEF has evolved dramatically. Rather than sequential addition of medications, contemporary evidence supports simultaneous initiation of all four medication classes, even in hospitalized patients with newly diagnosed disease 1, 2. This represents a paradigm shift from older guidelines.

1. Renin-Angiotensin System Inhibition

Start with an ACE inhibitor initially, then transition to an ARNI (sacubitril/valsartan) once the patient is stabilized 3, 1:

• ACE inhibitor starting doses: Enalapril 2.5 mg twice daily, Lisinopril 2.5-5 mg daily, or Ramipril 1.25 mg daily
• Target doses: Enalapril 10-20 mg twice daily, Lisinopril 20-40 mg daily, Ramipril 10 mg daily 1
• ARNI (sacubitril/valsartan): Start 24/26-49/51 mg twice daily, target 97/103 mg twice daily 1

Critical initiation steps 3:

• Review and potentially reduce diuretics 24 hours before starting
• Start low, go slow—begin with lowest dose
• Monitor BP, renal function, and electrolytes at 1-2 weeks, then after each dose increase
• Avoid potassium-sparing diuretics during initial ACE inhibitor titration
• Avoid NSAIDs completely

2. Beta-Blockers

Beta-blockers reduce mortality in all NYHA classes (II-IV) and should be started once the patient is relatively stable 3:

Evidence-based options 4, 1:

• Carvedilol: Start 3.125 mg twice daily, target 25 mg twice daily (<85 kg) or 50 mg twice daily (≥85 kg)
• Metoprolol succinate: Start 12.5-25 mg daily, target 200 mg daily
• Bisoprolol: Start 1.25 mg daily, target 10 mg daily

Key points:

• Patient must be on background ACE inhibitor therapy unless contraindicated 3
• Titrate over weeks to months to target doses 4
• Do NOT wait for ACE inhibitor to reach target before starting beta-blocker 5

3. Mineralocorticoid Receptor Antagonists (MRA)

Spironolactone or eplerenone improve survival, particularly in NYHA class III-IV patients 3:

• Spironolactone: Start 12.5-25 mg daily, target 25-50 mg daily 1
• Eplerenone: Start 25 mg daily, target 50 mg daily 1

Safety monitoring is critical 4:

• Check baseline potassium (<5.0 mmol/L) and creatinine (<250 μmol/L)
• Recheck potassium and creatinine after 4-6 days
• If potassium 5.0-5.5 mmol/L: reduce dose by 50%
• If potassium >5.5 mmol/L: stop medication
• Recheck weekly until stable

4. SGLT2 Inhibitors

The newest addition to foundational therapy—SGLT2 inhibitors reduce cardiovascular death and HF hospitalization regardless of diabetes status 1, 2:

• Dapagliflozin: 10 mg daily (both starting and target dose)
• Empagliflozin: 10 mg daily (both starting and target dose)

These can be started immediately, even during hospitalization for acute decompensation 1, 2.

Additional Therapies Based on Specific Indications

Diuretics (Symptomatic Relief)

Loop diuretics or thiazides are essential for congestion but do NOT improve mortality 3:

• Always combine with ACE inhibitor 3
• Use loop diuretics if GFR <30 ml/min (avoid thiazides alone) 3
• For persistent fluid retention: give loop diuretics twice daily 3
• For severe refractory cases: add metolazone with frequent electrolyte monitoring 3

For African American Patients

Add hydralazine/isosorbide dinitrate if symptomatic despite ACE inhibitor, beta-blocker, and MRA 6:

• Hydralazine: Start 25 mg three times daily, target 75 mg three times daily
• Isosorbide dinitrate: Start 20 mg three times daily, target 40 mg three times daily
• Fixed-dose combination: Start 20/37.5 mg (1 tablet) three times daily, target 2 tablets three times daily 1

This combination reduces mortality in African American patients with HFrEF 6.

Digoxin (Adjunctive Therapy)

Consider digoxin for persistent symptoms despite optimal GDMT or for rate control in atrial fibrillation 3:

• Dose: 0.125-0.25 mg daily (0.0625-0.125 mg in elderly) 3, 4
• Target serum level ≤1.0 ng/dL 7
• Contraindications: Bradycardia, 2nd/3rd-degree AV block, sick sinus syndrome, hypokalemia, hypercalcemia 3

ARBs (Alternative to ACE Inhibitors)

Use ARBs only if ACE inhibitors are not tolerated (typically due to cough or angioedema) 3:

• Candesartan: Start 4-8 mg daily, target 32 mg daily
• Valsartan: Start 40 mg twice daily, target 160 mg twice daily
• Losartan: Start 25-50 mg daily, target 150 mg daily 1

ARBs have fewer side effects than ACE inhibitors but unclear if equally effective for mortality reduction 3.

Critical Implementation Strategy

The evidence strongly supports rapid, simultaneous initiation rather than sequential addition 2. In a U.S. nationwide study, 82% of newly diagnosed HFrEF patients were eligible for quadruple therapy, yet only 15% received it 2. Projected absolute risk reduction in 12-month mortality with complete quadruple therapy was 10.4% compared to ACE inhibitor/beta-blocker alone (NNT=10) 2.

Practical Approach:

1. Start all four foundational medications simultaneously at initial low doses during hospitalization or at first outpatient visit 1, 2
2. Uptitrate each medication independently to target doses over weeks to months—do not wait for one to reach target before increasing another 5, 1
3. Monitor closely: BP, heart rate, renal function, and electrolytes after each change 3
4. Prioritize medications with mortality benefit (ACE inhibitor/ARNI, beta-blocker, MRA, SGLT2i) over symptomatic therapies 1

Common Pitfalls to Avoid:

• Do NOT use diuretics alone long-term—they activate neurohormonal systems and worsen outcomes 7
• Do NOT delay beta-blocker initiation until ACE inhibitor reaches target dose 5
• Do NOT avoid MRAs due to fear of hyperkalemia—monitor appropriately and adjust 4
• Do NOT forget SGLT2 inhibitors—they're now foundational, not optional 1, 2
• Do NOT use potassium-sparing diuretics during ACE inhibitor initiation 3

When to Refer to HF Specialist:

• Severe HF (NYHA class III-IV) 4
• Intolerance to low doses of foundational therapies 4
• Persistent symptoms despite optimal medical therapy 8
• Uncertainty about medication management in complex patients 6

Referral to HF specialists significantly improves GDMT initiation rates across all medication classes 9.